Manufacturer
PFIZER (PERTH) PTY. LTD.
 
Contents
Irinotecan HCl trihydrate
 
Indication
In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patient w/o prior chemotherapy for advanced disease or as a single agent in patients who have failed an established 5-FU containing treatment regimen.
 
Instruction
Monotherapy 100-125 mg/m2 over 30-90 min IV infusion once wkly or 200-250 mg/m2 over 30-90 min IV infusion once every 2 wk, or 300-350 mg/m2 over 30-90 min IV infusion once every 3 wk. Combination therapy Starting dose: 125 mg/m2 irinotecan, 500 mg/m2 bolus 5-FU & 20 mg/m2 bolus folinic acid for 6 wk or 180 mg/m2 irinotecan, 400 mg/m2 bolus 5-FU, 600 mg/m2 5-FU infusion & 200 mg/m2 folinic acid for 6 wk.
 
Drug interaction
Increased systemic exposure w/ CYP3A4 &/or UGT1A1 inhibitors. Increased exposure to SN-38 w/ ketoconazole & atazanavir sulfate. Reduced exposure to SN-38 w/ CYP3A-inducing anticonvulsant drugs eg, carbamazepine, phenobarb or phenytoin & St. John's wort. Prolonged neuromuscular blocking effects. Exacerbated adverse effects w/ antineoplastic agents. Enhanced lymphocytopenia w/ dexamethasone. Worsened diarrhea incidence or severity w/ laxatives. Dehydration w/ diuretics.